CClinicalTrials.gg
RecruitingNCT05321043Updated Nov 29, 2023

Risk Assessment of Indirect Exposure to the Environment in the Gastrointestinal Endoscopy Center

An interventional study of Vitamin B2 labeling in Infection Control, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Study summary

Study objective: To clarify the risk of exposure to indirect contact and transmission of environmental objects during digestive endoscopy diagnosis and treatment for patients and medical staff, simulating by using Vitamin B2 solution.

Study design: This is a case-only research.

Read the detailed description

In the study, the object surface of the digestive endoscopy room is preliminarily analyzed, and several key exposure units, such as potential high-frequency touch areas such as the surface of the bed unit, are screened and defined. A fluorescence photographing system is arranged in the digestive endoscopy room, and the exposure unit before treatment is photographed with the best excitation wavelength of the fluorescent marker as the light source, to get the experimental background reference. Then, patients undergoing digestive endoscopy in the same endoscopy work unit (usually half a day) are selected. Before entering the digestive center, the hands of patients are fluorescently marked with vitamin B2 mixed hand sanitizer 1ml (vitamin B2 0.12mg/ml). Meanwhile, the process of the gastroscopy is recorded by camera for the recognition of touch behaviors. Then, the doctors and nurses give routine care and procedure. Based on the fluorescence tracing and detection methods, the indoor light source is turned off after each selected endoscopy work unit, and the fluorescence residue on the surface of key exposed units is photographed. The environmental surfaces touched by the patient are sampled by the wiping method. Then the video of the gastroscopy process is analyzed for the recognition of touch behaviors. The dosage is detected by the Fluoro Max-4® fluorophotometer (HORIBA, Japan), which is quantified as a cumulative mass (μg) over all the exposure time.

02

Conditions studied

  • Infection Control

Browse trials for

Keywords

  • infection control
  • indirect contagion transmission
  • digestive endoscopy center
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 100 is below the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,115 studies on the registry; 463 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • During the study period, patients who were treated in the digestive endoscopy center of Beijing Union Medical College Hospital and planned to undergo gastroscopy. Age and gender are not limited temporarily.

Exclusion criteria

Exclusion Criteria:

  • Allergic to medical non-toxic fluorescent agent: Vitamin B2 aqueous solution.
  • Poor general condition, including severe cardiopulmonary disease, difficult to tolerate examination, and coagulation disorders.
  • Patients with contraindications to endoscopy.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Vitamin B2 labeled group

    A liquid of vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the patients' hands outside the endoscopy center.

    Other: Vitamin B2 labeling

Interventions

  • OtherVitamin B2 labeling

    Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.

06

What researchers measure

Primary outcomes

  1. Dosage of Indirect Contact Exposure of Environmental surfaces

    A liquid of Vitamin B2 and hand sanitizer (0.12mg/mL) is marked on the hands of every patient who is scheduled in the same endoscopy work unit (usually half a day) outside the endoscopy center. Then, the doctors and nurses conduct standard EGD procedure. After this endoscopy work unit is finished, the environmental surfaces touched by the patient are sampled by the wiping method. The dosage is detected by the Fluoro Max-4® fluorophotometer (HORIBA, Japan), which is quantified as a cumulative mass (μg) over all the exposure time.

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, 100730, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05321043
Lead sponsor
Peking Union Medical College Hospital
Collaborators
Tsinghua University
Responsible party
SHENGYU ZHANG (Associate Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Apr 11, 2022
Start date
Jul 1, 2022
Primary completion
Sep 1, 2024 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Nov 29, 2023

Study contacts

Shengyu Zhang, M.D.
Contact
pumchzsy@126.com
+8618501155701
Shengyu Zhang, MD
study director · Peking Union Medical College Hospital
Yuheng Zhang, MD candidate
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion